Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast

Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021


Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three and nine months ended September 30, 2021.

As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively.

Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020.

About Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. is a pharmaceutical company formerly focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. In March 2021, Odonate announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. Odonate has transitioned all patients in tesetaxel studies to appropriate alternative therapies or facilitated continuation of treatment with tesetaxel under compassionate use programs where appropriate.

ODONATE THERAPEUTICS, INC.

Condensed Balance Sheets

(in thousands, except par value and share amounts)

 

 

 

 

 

 

 

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

 

(Unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash

 

$

95,028

 

 

$

157,265

 

Prepaid expenses and other current assets

 

 

4,554

 

 

 

2,607

 

Total current assets

 

 

99,582

 

 

 

159,872

 

Property and equipment, net

 

 

1,833

 

 

 

2,286

 

Right-of-use lease assets

 

 

3,590

 

 

 

4,017

 

Restricted cash

 

 

714

 

 

 

714

 

Other

 

 

54

 

 

 

997

 

Total assets

 

$

105,773

 

 

$

167,886

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

11,661

 

 

$

14,168

 

Accrued expenses

 

 

17,892

 

 

 

12,247

 

Lease liabilities, current portion

 

 

744

 

 

 

658

 

Total current liabilities

 

 

30,297

 

 

 

27,073

 

Lease liabilities, less current portion

 

 

4,105

 

 

 

4,668

 

Total liabilities

 

 

34,402

 

 

 

31,741

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Common stock, $0.01 par value?100,000,000 shares authorized; 38,490,336 and 38,562,281 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively

 

 

368

 

 

 

367

 

Additional paid-in capital

 

 

507,210

 

 

 

502,205

 

Accumulated deficit

 

 

(436,207

)

 

 

(366,427

)

Total stockholders' equity

 

 

71,371

 

 

 

136,145

 

Total liabilities and stockholders' equity

 

$

105,773

 

 

$

167,886

 

ODONATE THERAPEUTICS, INC.

Condensed Statements of Operations

(Unaudited)

(in thousands, except share and per share amounts)

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

2,869

 

 

$

28,242

 

 

$

52,422

 

 

$

86,966

 

General and administrative

 

 

11,148

 

 

 

2,408

 

 

 

17,467

 

 

 

8,033

 

Total operating expenses

 

 

14,017

 

 

 

30,650

 

 

 

69,889

 

 

 

94,999

 

Loss from operations

 

 

(14,017

)

 

 

(30,650

)

 

 

(69,889

)

 

 

(94,999

)

Other income, net

 

 

20

 

 

 

173

 

 

 

109

 

 

 

935

 

Net loss

 

$

(13,997

)

 

$

(30,477

)

 

$

(69,780

)

 

$

(94,064

)

Net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.37

)

 

$

(0.93

)

 

$

(1.85

)

 

$

(3.00

)

Weighted-average shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

37,922,594

32,821,835

37,750,432

31,376,672

ODONATE THERAPEUTICS, INC.

Condensed Statements of Cash Flows

(Unaudited)

(in thousands)

 

 

 

 

 

 

Nine Months Ended

 

 

 

September 30,

 

 

 

2021

 

 

2020

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(69,780

)

 

$

(94,064

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Equity-based compensation expense

 

 

4,181

 

 

 

7,522

 

Depreciation and amortization

 

 

368

 

 

 

318

 

Non-cash lease expense

 

 

427

 

 

 

282

 

Loss on disposal of property and equipment

 

 

111

 

 

 

83

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses and other assets

 

 

(1,004

)

 

 

904

 

Accounts payable

 

 

(2,507

)

 

 

(1,559

)

Accrued expenses

 

 

5,645

 

 

 

5,110

 

Lease liabilities

 

 

(477

)

 

 

(225

)

Net cash used in operating activities

 

 

(63,036

)

 

 

(81,629

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(26

)

 

 

(416

)

Net cash used in investing activities

 

 

(26

)

 

 

(416

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock under employee stock plans

 

 

825

 

 

 

2,459

 

Proceeds from issuance of common stock, net of issuance costs

 

 

-

 

 

 

87,384

 

Net cash provided by financing activities

 

 

825

 

 

 

89,843

 

Net decrease in cash and restricted cash

 

 

(62,237

)

 

 

7,798

 

Cash and restricted cash, beginning of period

 

 

157,979

 

 

 

181,174

 

Cash and restricted cash, end of period

 

$

95,742

 

 

$

188,972

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

Initial recognition of right-of-use lease assets

 

$

-

 

 

$

2,861

 

Tenant improvement allowance

 

$

-

 

 

$

719

 

 


These press releases may also interest you

at 01:05
BeiGene, Ltd. , a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new regional office in Basel, Switzerland. BeiGene has built a European organization,...

at 01:00
BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI-enabled drug...

at 00:00
Clinical trial professionals need to harness the power within their clinical trial data. This free webinar will show them how to take control. There's no doubt the volume, variety and velocity of data has never been greater, with the number of unique...

at 00:00
Drug and device manufactures need to understand their company's culture of quality and how it might be improved. Have their efforts made to date fallen on deaf ears? Is there a way to measure what's working, and more importantly what's not, so...

16 mai 2022
In 2007, after many years in the recruiting industry and entrepreneurship in his DNA, TurningPoint's CEO & Founder, Ken Schmitt, decided it was time to change the standard for recruiting. He envisioned a high-touch, personalized approach to...

16 mai 2022
Mind Medicine (MindMed) Inc. , (NEO: MMED) (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced today that the registration statement on Form S-3, filed on May 4, 2022, was...



News published on 10 november 2021 at 17:20 and distributed by: